Sigilon Terminates Hemophilia A Project

Thanks to Dean Willett, Precision BioLogic Inc. for this heads-up. Dean alerts us to this press release [click] outlining Sigilon’s decision to terminate their hemophilia program. They were exploring the use of cell-based therapy and unfortunately were not successful. See the press release and Sigilon’s home page both offer a clear description of this interesting therapeutic approach.